These results suggest that the CDH1 mRNA upregulation occurs in the early stages of tumor development and the levels remain high as tumors progress to later stages across most carcinoma subtypes except for ovarian cancer, where downregulation of CDH1 mRNA is observed when the tumors progress from stage 2 to stage 3 (Fig. 2F). This evidence concerns the gene CDH1 and ovarian carcinoma.